Back to Directory

Cizzle Biotechnology

London
Founded 2006
Blood-based CIZ1B biomarker test for early-stage lung cancer detection

Cizzle Biotechnology is a UK-based diagnostics company developing a non-invasive blood test for the early detection of lung cancer.

The company's CIZ1B biomarker test identifies a stable plasma biomarker highly correlated with early-stage disease, offering an alternative to imaging or biopsy procedures.

Cizzle's test is licensed for use in North America and is undergoing validation with UK clinical laboratory partners, serving healthcare providers and diagnostic laboratories working towards earlier cancer detection and treatment.

BiotechOncologyDiagnostics & Biomarkers
Respiratory DiseaseClinical DiagnosticsLiquid Biopsy

Is this your company?

Claim this page to receive a verified badge and keep your profile up to date.

Claim page

Latest News

Company News16 Jun 2026

Cizzle Biotechnology's CIZ1B Test Gains CLIA Accreditation in the US

Cizzle Biotechnology's CIZ1B lung cancer biomarker blood test has received CLIA accreditation for clinical use in the US, through CLIA-certified laboratory OmniHealth Diagnostics in Dallas, Texas. The company also confirmed patent grants in the US and Canada, and guaranteed minimum royalties under its licensing agreement with North American partner Cizzle Bio Inc rose to approximately $5.9 million.

Source: Cizzle BiotechnologyRead source